Patents by Inventor Claudio Soto

Claudio Soto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220137073
    Abstract: Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicants: Amprion, Inc., Board of Regents of the University of Texas System
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz, Nicolas Mendez Dinamarca
  • Patent number: 11249092
    Abstract: Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: February 15, 2022
    Assignee: Amprion, Inc.
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz, Nicolas Mendez Dinamarca
  • Publication number: 20210223268
    Abstract: A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (?S) protein with a pre-incubation mixture comprising a monomeric ?S substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded ?S aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded ?S aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.
    Type: Application
    Filed: January 21, 2021
    Publication date: July 22, 2021
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Luis Concha
  • Publication number: 20210208166
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 8, 2021
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20210164998
    Abstract: A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (?S) protein with a pre-incubation mixture comprising a monomeric ?S substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded ?S aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded ?S aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.
    Type: Application
    Filed: January 21, 2021
    Publication date: June 3, 2021
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Luis Concha
  • Patent number: 10989718
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 27, 2021
    Assignees: Amprion, Inc., The Board of Regents of the University of Texas System
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20210102961
    Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 8, 2021
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
  • Publication number: 20190353669
    Abstract: Methods and kits for evaluating a subject for a brain injury are described. The method may include providing at least one biological sample from the subject having or suspected of having the brain injury. The method may include conducting one or more amplification reactions, including contacting a portion of the biological sample with a monomeric, folded tau protein to form an incubation mixture. Each amplification reaction may include determining a presence or amount of the misfolded tau protein in the biological sample according to the amplified portion of the misfolded tau protein. Methods for evaluating the risk of neurodegenerative disease or disorder in a subject having suffered from brain injury are also described.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Russell M. Lebovitz, Benedikt K. Vollrath, Luis Concha, Claudio Soto-Jara
  • Publication number: 20190137515
    Abstract: Described are methods for estimating misfolded protein concentration in fluids and tissues by quantitative PMCA.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 9, 2019
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Patent number: 10215763
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: February 26, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Publication number: 20180335438
    Abstract: Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 22, 2018
    Applicants: Amprion, Inc., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz, Nicolas Mendez Dinamarca
  • Publication number: 20180196068
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
  • Publication number: 20180196069
    Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
  • Patent number: 9910049
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 6, 2018
    Assignees: AMPRION, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077110
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077111
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077112
    Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20110311997
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Application
    Filed: May 18, 2011
    Publication date: December 22, 2011
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Publication number: 20110086057
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 14, 2011
    Applicant: MERCK SERONO SA
    Inventors: Claudio Soto-Jara, Claudia Pena-Rossi
  • Patent number: 7858765
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 28, 2010
    Assignee: Merck Serono SA
    Inventors: Claudio Soto-Jara, Claudia Pena-Rossi